White Paper

Clinical Applications of Gadopiclenol in Pediatric MRI
Credits: 0.5 Category A, ARRT and CRA   |  Format: Text Self-Study  
Release Date: March 1, 2024  |  Expiration Date: February 28, 2027
Gadolinium-based contrast agents (GBCAs) continue to advance the diagnostic value of magnetic resonance imaging (MRI). Given that children may undergo repeat exams over their lifetime, weighing the benefits of contrast with its associated risks is crucial.
In this CE-accredited paper, Shreyas Vasanawala, MD, PhD, Division Chief of Pediatric Radiology at Stanford Health Care, Stanford Medicine Children's Health, shares his clinical experience and discusses considerations for selecting and utilizing GBCAs in pediatric MRI. With special focus on structure and relaxivity, Dr. Vasanawala presents case studies that demonstrate the clinical impact of the newest GBCA, gadopiclenol.
Educational Objectives
Upon completion of this CE-accredited activity the healthcare provider should be able to:
  • Describe the history of GBCA use in contrast-enhanced MRI, with focus on pediatric imaging.
  • Identify key physicochemical properties that can guide the selection and use of GBCAs in children.
  • Discuss the use of gadopiclenol in pediatric clinical scenarios and its impact on patient management.
This program is made possible through an unrestricted educational grant from Bracco Diagnostics.